Neos Therapeutics Inc (NASDAQ:NEOS) Given Consensus Rating of “Buy” by Analysts
Shares of Neos Therapeutics Inc (NASDAQ:NEOS) have been assigned a consensus recommendation of “Buy” from the six brokerages that are currently covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among brokers that have covered the stock in the last year is $7.25.
A number of research analysts have recently commented on NEOS shares. BMO Capital Markets dropped their target price on shares of Neos Therapeutics from $4.00 to $3.00 and set a “market perform” rating for the company in a report on Monday, August 12th. Zacks Investment Research cut shares of Neos Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, Oct ...